MD - MEDNAX INC （）

From the deeper analysis of the numbers, I believe Pediatrix has the economic pillars to re-rate to the upside. Click here to see why MD stock is a buy at the current levels.

As I was preparing to write about cheap stocks to buy that could increase by ten times over the next few years, I wondered what measuring stick I should use to appropriately identify names that were down but definitely not out. I looked online for a few ideas. For example, NerdWallet recently defined cheap stocks as S&P 500 companies whose share price traded between $5 and $20, but had risen so far this year. InvestorPlace contributor Brian Paradza focused on the PEG ratio — defined as the price–earnings ratio divided by firms’ earnings per share growth — to find some stocks to buy and hold for the long haul. Lastly, Barron’s used the enterprise value-sales ratio to find cheap tech stocks . The publication noted that the ratio factors in cash and debt, instead of just market capitalization, making it a more compelling metric than price-sales. So, based very loosely on these three metrics, I’m going to select seven stocks from the S&P 1500 from seven different sectors. I believe that all of these names have a shot at appreciating ten times by 2027.

According to Benzinga Pro, during Q2, Mednax (NYSE: MD ) earned $27.14 million, a 228.05% increase from the preceding quarter. Mednax also posted a total of $486.03 million in sales, a 0.79% increase since Q1. In Q1, Mednax brought in $482.23 million in sales but lost $21.19 million in earnings. Why Is ROIC Significant? Return on Invested Capital is a measure of yearly pre-tax profit relative to capital invested by a business. Changes in earnings and sales indicate shifts in a company''s ROIC. A higher ROIC is generally representative of successful … Full story available on Benzinga.com

Pediatrix has idiosyncratic risk drivers that have yet to be priced in at the market level, by estimate. MD''s price action points to a reversal from recent lows.

Mednax found using ticker (MD) have now 10 analysts in total covering the stock. The consensus rating is ''Hold''. The target price ranges between 30 and 14 calculating the mean target price we have 21. With the stocks previous close at 21.32 this now indicates there is a potential downside of -1.5%. The day 50 moving average is 19.84 and the 200 day MA is 24.3. The market cap for the company is $1,861m. You can visit the company''s website by visiting: https://www.mednax.com [stock_market_widget type="chart" template="basic" color="green" assets="MD" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $1,833m based on the market concensus. MEDNAX, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.

Mednax (MD) said it will change its corporate name to Pediatrix Medical Group Inc., effective after the close of the market on July 1.The company added that its common stock will…

Mednax with ticker code (MD) now have 10 analysts covering the stock with the consensus suggesting a rating of ''Hold''. The target price ranges between 30 and 14 calculating the mean target price we have 21.5. With the stocks previous close at 20.38 this now indicates there is a potential upside of 5.5%. The day 50 moving average is 20.77 and the 200 day moving average is 25.1. The company has a market capitalisation of $1,744m. Company Website: https://www.mednax.com [stock_market_widget type="chart" template="basic" color="green" assets="MD" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $1,840m based on the market concensus. MEDNAX, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)---- $MD--Mednax to Present at 2022 J.P. Morgan Global High Yield and Leveraged Finance Conference

Mednax Inc (NYSE: MD ) reports Q4 adjusted EPS of $0.52 , more than double from $0.25 a year ago and beating the consensus of $0.44. Q4 revenues reached $498.5 million, compared to $416.6 million for the prior-year period and beating the consensus of $483.83 million. Mednax''s overall same-unit revenue increased by 17.6%, modestly complemented by net acquisition activity. Same-unit revenue from net reimbursement-related … Full story available on Benzinga.com

Mednax is a leading provider of physician services including newborn, maternal-fetal, pediatric cardiology and other pediatric subspecialty care. Our national network is comprised of affiliated physicians who provide clinical care in 38 states and Puerto Rico. At December 31, 2021, our national network comprised over 2,400 affiliated physicians,… The post MEDNAX, INC. – 10-K – MANAGEMENT''S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS appeared first on InsuranceNewsNet .